Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429372 · ClinicalTrials.gov registry record · Phase 2
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05429372 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT05429372, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
Interventions
- GENETIC PF-06939926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05429372
The ClinicalTrials.gov registry entry for NCT05429372 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06939926 is the first listed.
NCT05429372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05429372 about?
NCT05429372 is a clinical study titled "Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy". The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
What is the current status of trial NCT05429372?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-08-08. Estimated completion is 2025-10-03.
What interventions are being tested in trial NCT05429372?
The interventions under investigation include: PF-06939926 (GENETIC).
Who is sponsoring clinical trial NCT05429372?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.